Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Invested Capital (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Invested Capital for 3 consecutive years, with $155.5 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Invested Capital fell 30.44% year-over-year to $155.5 million, compared with a TTM value of $155.5 million through Sep 2024, down 30.44%, and an annual FY2023 reading of $213.9 million, up 41.51% over the prior year.
  • Invested Capital was $155.5 million for Q3 2024 at Oramed Pharmaceuticals, down from $176.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $223.6 million in Q3 2023 and bottomed at $150.1 million in Q1 2023.
  • Average Invested Capital over 3 years is $171.6 million, with a median of $155.5 million recorded in 2024.
  • The sharpest move saw Invested Capital surged 46.0% in 2023, then plummeted 30.44% in 2024.
  • Year by year, Invested Capital stood at $151.2 million in 2022, then skyrocketed by 41.51% to $213.9 million in 2023, then decreased by 27.29% to $155.5 million in 2024.
  • Business Quant data shows Invested Capital for ORMP at $155.5 million in Q3 2024, $176.2 million in Q2 2024, and $197.8 million in Q1 2024.